Who are Envlomet SR Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dexmedetomidine 80 µg, Butorphanol and dexmedetomindine, Dexmedetomidine 0.5μg／kg, Intra-nasal Dexmedetomidine, ropivacaine plus clonidine, lofexidine HCl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/envlomet-sr-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Envlomet SR Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Envlomet SR Tablet (Envlomet SR Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Pain management.

phase 2 Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Envlomet SR Tablet (Envlomet SR Tablet) — Daewoong Pharmaceutical Co. LTD.. Envlomet SR Tablet is a sustained-release formulation of a selective alpha-2 adrenergic receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Envlomet SR Tablet TARGET	Envlomet SR Tablet	Daewoong Pharmaceutical Co. LTD.	phase 2	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
dexmedetomidine 80 µg	dexmedetomidine 80 µg	Fayoum University Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Butorphanol and dexmedetomindine	Butorphanol and dexmedetomindine	The Affiliated Hospital of Qingdao University	marketed	Opioid agonist-antagonist combined with alpha-2 adrenergic agonist	Opioid receptors (kappa, sigma, mu) and alpha-2 adrenergic receptors
Dexmedetomidine 0.5μg／kg	Dexmedetomidine 0.5μg／kg	Eye & ENT Hospital of Fudan University	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Intra-nasal Dexmedetomidine	Intra-nasal Dexmedetomidine	University of Massachusetts, Worcester	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
ropivacaine plus clonidine	ropivacaine plus clonidine	University Hospital, Lille	marketed	Local anesthetic with adjuvant alpha-2 agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine)
lofexidine HCl	lofexidine HCl	USWM, LLC (dba US WorldMeds)	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

Allergan · 3 drugs in this class
Eye & ENT Hospital of Fudan University · 2 drugs in this class
National Cancer Institute, Egypt · 2 drugs in this class
The University of Hong Kong · 2 drugs in this class
Sindh Institute of Urology and Transplantation · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Envlomet SR Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/envlomet-sr-tablet. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing